(Q37109503)

18 August 2017

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma (English)

1 reference

18 August 2017

1 reference

11

Richard Gorlick

1 reference

18 August 2017

Tadahiko Kubo

1

1 reference

18 August 2017

Sajida Piperdi

2

1 reference

18 August 2017

Jeremy Rosenblum

3

1 reference

18 August 2017

Cristina R Antonescu

4

1 reference

18 August 2017

Wen Chen

5

1 reference

18 August 2017

Han-Soo Kim

6

1 reference

18 August 2017

Andrew G Huvos

7

1 reference

18 August 2017

Rebecca Sowers

8

1 reference

18 August 2017

Paul A Meyers

9

1 reference

18 August 2017

John H Healey

10

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

112

1 reference

18 August 2017

10

1 reference

18 August 2017

2119-2129

1 reference

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

18 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Human osteoblasts synthesize and respond to platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23437

7 January 2021

Identifiers

DOI

10.1002/CNCR.23437

1 reference

18 August 2017

1 reference